The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Agenus; Amgen; AstraZeneca; BeiGene; Bristol-Myers Squibb; Celon Pharma; Jacobio; Janssen; Loxo; MacroGenics; Menarini; MSD; Pfizer; Rhizen Pharmaceuticals; Roche; Sanofi; Takeda
Consulting or Advisory Role - Boehringer Ingelheim
Research Funding - Agenus; Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb
A phase 1, open-label, multicenter study evaluating MK-1084 as monotherapy and in combination with other therapies in patients with KRAS G12C mutant advanced solid tumors.
 
Iwona A. Lugowska
No Relationships to Disclose
 
Carlos Rojas
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Knight Therapeutics/Biotoscana; Merck Sharp & Dohme; Pfizer; Roche
Research Funding - AstraZeneca; Bristol-Myers Squibb/Celgene; Knight Therapeutics/Biotoscana; Merck; Pfizer; Roche
Expert Testimony - AstraZeneca; Bristol-Myers Squibb; Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Anastasios Stathis
Consulting or Advisory Role - AstraZeneca (Inst); Bayer (Inst); Janssen Oncology (Inst); Lilly (Inst); Novartis (Inst); Roche (Inst)
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Cellestia Biotech (Inst); Debiopharm Group (Inst); Incyte (Inst); Lilly (Inst); Loxo (Inst); MEI Pharma (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Philogen (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Incyte (Inst)
 
Susanne Weindler
Consulting or Advisory Role - Amgen (Inst)
Research Funding - BMS Brazil (Inst); MSD (Inst)
Travel, Accommodations, Expenses - Lilly (Inst); Vifor pharma (Inst)
 
Abhijit Pal
Travel, Accommodations, Expenses - MSD
 
Eduardo Castanon Alvarez
Honoraria - Bms spain; Gilead Sciences; GlaxoSmithKline; MSD Oncology; Roche; Roche
Consulting or Advisory Role - BeiGene
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bms Spain; MSD; Roche; Roche
 
Jacek Mackiewicz
Consulting or Advisory Role - Bristol-Myers Squibb; MSD
Speakers' Bureau - Bristol-Myers Squibb; GlaxoSmithKline; MSD; Novartis; Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb; GlaxoSmithKline; MSD; Novartis; Pierre Fabre; Roche
 
Marcelo Garrido
Consulting or Advisory Role - AstraZeneca; MSD; Roche
Speakers' Bureau - Bayer; Bristol-Myers Squibb; MERCK
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst)
Expert Testimony - AstraZeneca
Travel, Accommodations, Expenses - Roche
 
Mehmet Ali Nahit Sendur
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Novartis; Pfizer; Roche; Takeda
Speakers' Bureau - Astellas Pharma; Novartis; Pfizer; Roche; Takeda
 
Nehal J. Lakhani
Consulting or Advisory Role - Ikena Oncology; SK Life Sciences
Research Funding - Alexo Therapeutics (Inst); Alkermes (Inst); Alpine Immune Sciences (Inst); Alpine Immune Sciences (Inst); Apexian Pharmaceuticals (Inst); Ascentage Pharma (Inst); Astellas Pharma (Inst); BeiGene (Inst); Biosplice (Inst); Celgene (Inst); Celgene (Inst); Constellation Pharmaceuticals (Inst); Coordination Therapeutics (Inst); CytomX Therapeutics (Inst); Epizyme (Inst); Forty Seven (Inst); Genmab (Inst); Genmab (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Helsinn Therapeutics (Inst); Ikena Oncology (Inst); Ikena Oncology (Inst); Incyte (Inst); InhibRx (Inst); Innovent Biologics (Inst); Jounce Therapeutics (Inst); KSQ Therapeutics (Inst); LAM Therapeutics (Inst); Lilly (Inst); Livzon (Inst); Loxo (Inst); Macrogenics (Inst); Merck (Inst); Mersana (Inst); Northern Biologics (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst); Repare Therapeutics (Inst); Sapience Therapeutics (Inst); Sapience Therapeutics (Inst); Seagen (Inst); Servier (Inst); Shattuck Labs (Inst); SK Life Sciences (Inst); Symphogen (Inst); Tesaro (Inst); Tizona Therapeutics, Inc. (Inst)
 
Sophia Frentzas
Consulting or Advisory Role - GOG Foundation; MSD Oncology
 
Rafal Dziadziuszko
Honoraria - AstraZeneca; Bristol-Myers Squibb; MSD Oncology; Roche/Genentech; Takeda
Travel, Accommodations, Expenses - AstraZeneca; Pfizer; Roche
 
Adrian G. Sacher
Research Funding - AstraZeneca; BMS; Genentech/Roche
(OPTIONAL) Uncompensated Relationships - AstraZeneca; Genentech/Roche
 
Kazushige Wakuda
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Janssen; Lilly; MSD; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Abbvie; Amgen; AZD; Chugai Pharma; Daiichi Sankyo; MSD; Novartis
 
Terufumi Kato
Employment - Lilly (I)
Honoraria - Amgen; AstraZeneca; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; GlaxoSmithKline; Janssen; Lilly; Merck KGaA; Merck Sharp & Dohme; Novartis; Ono Pharmaceutical; Pfizer; Roche; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca; BeiGene; DaiichiSankyo; Janssen; Merck KGaA; MSD; Novartis; Pfizer
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer; BeiGene (Inst); Blueprint Medicines (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Haihe Biopharma (Inst); Janssen (Inst); Lilly (Inst); Merck KGaA (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Takeda (Inst); Turning Point Therapeutics (Inst)
 
Ruth Perets
Honoraria - GlaxoSmithKline; Merck Sharp & Dohme
Consulting or Advisory Role - 1E Therapeutics; Clexio Biosciences Ltd.; GalMed Pharmacueticals; Gilboa Therapeutics; Simplivia
Travel, Accommodations, Expenses - Merck Sharp & Dohme
 
Omar Orlando Castillo Fernandez
Honoraria - ASOFARMA; AstraZeneca; Novartis; Pfizer; Roche Pharma AG
Consulting or Advisory Role - Asofarma; GlaxoSmithKline; Janssen Oncology
Research Funding - MSD Oncology; Novartis; Roche; Roche
Travel, Accommodations, Expenses - Merck Serono; Novartis; Pfizer; Roche
 
Thomas Jemielita
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Yewon Choi
Employment - MSD
Stock and Other Ownership Interests - Merck
 
Rosalyn A. Juergens
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; Jazz Pharmaceuticals; Merck Sharp & Dohme; Mirati Therapeutics; Novartis Canada Pharmaceuticals Inc; Roche Canada; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; EMD Serono; Fusion Pharmaceuticals; Janssen Oncology; Jazz Pharmaceuticals; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche Canada; Sanofi/Regeneron; Takeda
Research Funding - Alkermes (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bold Therapeutics (Inst); Bristol-Myers Squibb (Inst); Fusion Pharmaceuticals (Inst); Janssen (Inst); Macrogenics (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst)